Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2024 | – | -$3.01 | |
| May 10, 2024 | – | -$2.41 | |
| Mar 25, 2024 | – | -$1.89 | |
| Nov 8, 2023 | – | -$1.51 | |
| Aug 10, 2023 | -$4.51 | -$4.33 | Beat |
| May 10, 2023 | -$2.70 | -$15.62 | Miss |